# Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum

> **NCT01355497** · PHASE3 · COMPLETED · sponsor: **GTx** · enrollment: 330 (actual)

## Conditions studied

- Muscle Wasting
- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** GTx-024
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01355497
- **Lead sponsor:** GTx
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-07
- **Primary completion:** 2013-05
- **Final completion:** 2014-06
- **Target enrollment:** 330 (ACTUAL)
- **Last updated:** 2020-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01355497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01355497, "Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer (NSCLC) on First Line Platinum". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01355497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*